Page 14«..10..13141516..2030..»

Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate™

Posted: November 20, 2024 at 2:48 am

Targeting Transformative Solutions for Aplastic Anemia and Beyond

Read more:
Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate™

Posted in Global News Feed | Comments Off on Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate™

Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference

Posted: November 20, 2024 at 2:48 am

REDWOOD CITY, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will attend the Piper Sandler 36th Annual Healthcare Conference, being held December 3-5, 2024, in New York, New York.

Excerpt from:
Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference

Posted in Global News Feed | Comments Off on Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

Posted: November 20, 2024 at 2:48 am

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

More:
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

Posted in Global News Feed | Comments Off on Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors

Posted: November 20, 2024 at 2:48 am

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a multi-asset, clinical stage, disease-agnostic life science company delivering an efficient model for compound development, today announces the appointment of Simon Fry to its Board of Directors.

More:
Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors

Posted in Global News Feed | Comments Off on Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors

Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance…

Posted: November 20, 2024 at 2:48 am

WARREN, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, has announced financial results for the fiscal quarter ending September 30, 2024, and filed its quarterly report on Form 10-Q with the Securities and Exchange Commission.

Link:
Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance...

Posted in Global News Feed | Comments Off on Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance…

Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program

Posted: November 20, 2024 at 2:48 am

FREMONT, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) announced today that it has been named “Overall BioTech Company of the Year” in the fourth annual BioTech Breakthrough Awards program. This program is conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products, and services around the globe. This year’s program attracted thousands of nominations from 14 different countries throughout the world, serving as a global recognition platform that encourages bold ideas and solutions that will shape the future of biotechnology.

Go here to see the original:
Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program

Posted in Global News Feed | Comments Off on Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

Posted: November 20, 2024 at 2:48 am

November 20, 2024, 7:00 AM CET

See original here:
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

Posted in Global News Feed | Comments Off on argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

Posted: November 12, 2024 at 2:47 am

NEWTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Stifel Healthcare Conference on Monday, Nov. 18, 2024, at 11:30 a.m. ET.

The rest is here:
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

Posted in Global News Feed | Comments Off on Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

Celldex Therapeutics to Present at Upcoming Investor Conferences

Posted: November 12, 2024 at 2:47 am

HAMPTON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences:

Read the original here:
Celldex Therapeutics to Present at Upcoming Investor Conferences

Posted in Global News Feed | Comments Off on Celldex Therapeutics to Present at Upcoming Investor Conferences

Assertio Reports Third Quarter 2024 Financial Results

Posted: November 12, 2024 at 2:47 am

Third Quarter Total Net Product Sales of $28.7 Million

Read the original:
Assertio Reports Third Quarter 2024 Financial Results

Posted in Global News Feed | Comments Off on Assertio Reports Third Quarter 2024 Financial Results

Page 14«..10..13141516..2030..»